Chief Operating Officer
Ms. Lime joined Sedia in 2019 and was appointed Chief Operating Officer in 2021. Prior to her role at Sedia, she provided operational leadership to Yecuris Corporation from 2015 to 2018, a biotechnology company providing human hepatocytes in a mouse model and research services. Ms. Lime held multiple positions at Oligos Etc. from 2002 – 2016. Her last role was President and CEO, where she provided the mission and vision, operational leadership, and managed the $5 million revenue-generating custom, chemical manufacturing operation. She has had full accountability for product profitability and quality, short and long-range strategic plans, operating plans and budgets, and monthly reporting to the Board of Directors. After the acquisition of Oligos Etc., Ms. Lime remained employed with the acquiring company, Integrated DNA Technologies, until the transfer of all assets and operations to their headquarters in Iowa. From 1990 – 2002, Ms. Lime was at OraSure Technologies Inc. (NASDAQ: OSUR) and promoted to positions of increasing responsibility. Functional areas included: manufacturing, quality control, operations and quality assurance. A few key accomplishments of Ms. Lime’s career is increasing manufacturing output for one product line by more than 300% in one year; developed and implemented a turnaround strategy resulting in strategic buyout; integrating the quality systems of Epitope and STC Technologies post-acquisition, serving on Design Review Boards for new products, playing a key role in the development of oral fluid diagnostics (including FDA approval and ISO certification) and championing efforts to bring manufacturing in-house, leading to $2 million cost saving in the first year alone. In her tenure, Ms. Lime participated in eleven FDA inspections and five CE Marking surveillance audits. Ms. Lime received her B.S. in General Science from the University of Oregon.